Wechselwirkungen · Baraclude
Baraclude 0.05 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 27
HOS-114620 · Präparat HOS-094121
Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of either medicinal product. Apart from lamivudine, adefovir dipivoxil and tenofovir disoproxil fumarate, the effects of coadministration of entecavir with medicinal products that are excreted renally or affect renal function have not been evaluated. Patients should be monitored closely for adverse reactions when entecavir is coadministered with such medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): adefovir dipivoxil (HOS-110478) lamivudine (HOS-085829) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:10:00Z · SHA-256 5288f9187061003c75d2d5158a207cf313073c14cbda3e6d995b2fa35b53697e · Passage ef6e707db8bf020283aef0686fde0997ef114b457c47c0f7e75e63cded1ae9f1 · Zeichen 0–591 im Abschnitt